{
    "organizations": [],
    "uuid": "c41f8eaa46bb6a5584493d3b1520355dd32ba093",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-glenmark-pharma-gets-permission-fr/brief-glenmark-pharma-gets-permission-from-cdsco-for-phase-iib-dose-range-finding-study-for-grc-27864-idUSFWN1PA039",
    "ord_in_thread": 0,
    "title": "BRIEF-Glenmark Pharma Gets Permission From CDSCO For Phase IIb Dose Range Finding Study For GRC 27864",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 15 (Reuters) - Glenmark Pharmaceuticals Ltd:\n* GETS PERMISSION BY CENTRAL DRUGS STANDARD CONTROL ORGANIZATION FOR PHASE IIB DOSE RANGE FINDING STUDY FOR GRC 27864 Source text - bit.ly/2mEqR6R Further company coverage:\n ",
    "published": "2018-01-15T15:41:00.000+02:00",
    "crawled": "2018-01-16T13:35:36.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "glenmark",
        "pharmaceutical",
        "ltd",
        "get",
        "permission",
        "central",
        "drug",
        "standard",
        "control",
        "organization",
        "phase",
        "iib",
        "dose",
        "range",
        "finding",
        "study",
        "grc",
        "source",
        "text",
        "company",
        "coverage"
    ]
}